| Elizabeth K Vonderhaar, MD | |
|
402 Keene St, 3rd Floor, Columbia, MO 65201-6986 | |
| (573) 499-6084 | |
| (573) 499-6084 |
| Full Name | Elizabeth K Vonderhaar |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 402 Keene St, Columbia, Missouri |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770711947 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 2009017187 (Missouri) | Primary |
| Entity Name | Anchorage Women's Clinic At Providence Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265496061 PECOS PAC ID: 9032102124 Enrollment ID: O20040405001651 |
News Archive
The New York Times reports on a lack of chemistry between President Barack Obama and leading Republicans such as Rep. John A. Boehner, the House Republican leader, and Senate Minority Leader Mitch McConnell.
Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.
Provenge, developed by Dendreon Corporation, is the first approved "treatment that uses a so-called cancer vaccine, a drug that trains the body's own immune system to fight the disease," The New York Times reports.
MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
BonAlive Biomaterials Ltd, a manufacturer of implantable medical devices and an emerging leader in indications involving the treatment of chronically infected bone, and Olympus Biotech International Ltd, a wholly owned company of Olympus Corporation focused on minimally-invasive regenerative therapies in bone and soft tissues, today announced the signing of a multi-year exclusive distribution agreement.
› Verified 9 days ago
| Entity Name | Alaska Womens Health Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083890180 PECOS PAC ID: 7012090210 Enrollment ID: O20080212000034 |
News Archive
The New York Times reports on a lack of chemistry between President Barack Obama and leading Republicans such as Rep. John A. Boehner, the House Republican leader, and Senate Minority Leader Mitch McConnell.
Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.
Provenge, developed by Dendreon Corporation, is the first approved "treatment that uses a so-called cancer vaccine, a drug that trains the body's own immune system to fight the disease," The New York Times reports.
MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
BonAlive Biomaterials Ltd, a manufacturer of implantable medical devices and an emerging leader in indications involving the treatment of chronically infected bone, and Olympus Biotech International Ltd, a wholly owned company of Olympus Corporation focused on minimally-invasive regenerative therapies in bone and soft tissues, today announced the signing of a multi-year exclusive distribution agreement.
› Verified 9 days ago
| Entity Name | Obhg Alaska Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740697069 PECOS PAC ID: 7113233834 Enrollment ID: O20150826000621 |
News Archive
The New York Times reports on a lack of chemistry between President Barack Obama and leading Republicans such as Rep. John A. Boehner, the House Republican leader, and Senate Minority Leader Mitch McConnell.
Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.
Provenge, developed by Dendreon Corporation, is the first approved "treatment that uses a so-called cancer vaccine, a drug that trains the body's own immune system to fight the disease," The New York Times reports.
MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
BonAlive Biomaterials Ltd, a manufacturer of implantable medical devices and an emerging leader in indications involving the treatment of chronically infected bone, and Olympus Biotech International Ltd, a wholly owned company of Olympus Corporation focused on minimally-invasive regenerative therapies in bone and soft tissues, today announced the signing of a multi-year exclusive distribution agreement.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth K Vonderhaar, MD 3260 Providence Dr, Suite 322, Anchorage, AK 99508-4661 Ph: (907) 563-5151 | Elizabeth K Vonderhaar, MD 402 Keene St, 3rd Floor, Columbia, MO 65201-6986 Ph: (573) 499-6084 |
News Archive
The New York Times reports on a lack of chemistry between President Barack Obama and leading Republicans such as Rep. John A. Boehner, the House Republican leader, and Senate Minority Leader Mitch McConnell.
Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.
Provenge, developed by Dendreon Corporation, is the first approved "treatment that uses a so-called cancer vaccine, a drug that trains the body's own immune system to fight the disease," The New York Times reports.
MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
BonAlive Biomaterials Ltd, a manufacturer of implantable medical devices and an emerging leader in indications involving the treatment of chronically infected bone, and Olympus Biotech International Ltd, a wholly owned company of Olympus Corporation focused on minimally-invasive regenerative therapies in bone and soft tissues, today announced the signing of a multi-year exclusive distribution agreement.
› Verified 9 days ago
Rose Elizabeth Todd, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1020 Hitt St, Columbia, MO 65212 Phone: 573-499-6084 Fax: 573-499-6088 | |
Dr. Madalyn Michelle Barnett, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 402 N Keene St, Columbia, MO 65201 Phone: 573-499-6084 Fax: 573-499-6088 | |
Dr. Abby Marie Lombardi, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 402 N Keene St # Dc570.00, Columbia, MO 65201 Phone: 573-499-6084 Fax: 573-499-6088 | |
Dr. Kaley Holloway Hankins, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 402 N Keene St, Columbia, MO 65201 Phone: 573-499-6084 Fax: 573-499-6088 | |
Dr. Michael S Cardwell, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 500 N. Keene St, Suite 406, Columbia, MO 65201 Phone: 573-499-6041 Fax: 573-499-6091 | |
Breton Foster Barrier, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2325 Smiley Ln, Columbia, MO 65202 Phone: 573-817-3535 Fax: 573-817-3536 | |
Katlynn Davis, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1 Hospital Dr, Columbia, MO 65212 Phone: 573-499-6084 |